Shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) were down 3.1% during mid-day trading on Friday . The stock traded as low as $3.11 and last traded at $3.15, with a volume of 183,709 shares traded. The stock had previously closed at $3.25.

Several analysts have issued reports on ANTH shares. HC Wainwright started coverage on shares of Anthera Pharmaceuticals in a research report on Friday, July 8th. They set a “buy” rating and a $10.00 price target on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Thursday, June 9th. FBR & Co reaffirmed a “hold” rating on shares of Anthera Pharmaceuticals in a research report on Monday, June 20th. Finally, Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $9.58.

The company’s market cap is $129.93 million. The firm’s 50-day moving average is $3.19 and its 200 day moving average is $3.41.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.01. On average, equities research analysts predict that Anthera Pharmaceuticals Inc. will post ($1.26) EPS for the current fiscal year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.